MetaCap

Actinium Pharmaceuticals (Delaware) (ATNM) vs Cue Biopharma (CUE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Cue Biopharma (CUE) over the past year, losing 21.1% versus a loss of 76.8%. Over five years, ATNM leads with a -85.6% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $33.0 million), about 1.1 times the size.

Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -37652.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATNM-21.05%CUE-76.75%
+122%+14%-94%
Nov 21, 20251 yearNov 20, 2026
ATNM-86.22%CUE-99.07%
+79%-14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATNM versus CUE key metrics
MetricATNMCUE
Share price$1.05$4.15
Market cap$33.01M$34.69M
1-day change-1.87%-7.78%
YTD return-22.79%-54.64%
1-year return-21.05%-76.75%
5-year return-85.60%-98.92%
P/E ratio (TTM)2.44—
EPS (TTM)$0.43$-27.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$90.00K$27.47M
Revenue growth (YoY)—+195.75%
Net income (latest FY)$-33.89M$-26.60M
Operating margin-40274.44%-96.67%
Net margin-37652.22%-96.85%
52-week high$1.72$45.50
52-week low$0.735$2.83
Distance from 52-week high-38.95%-90.88%
Analyst consensusnonenone
Avg. price target upside+242.86%+2020.48%
Average volume193.83K567.02K
Shares outstanding31.44M8.36M
Employees2729
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATNM has outperformed CUE by 55.7 percentage points over the past year.
  • Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -37652.2 cents for Actinium Pharmaceuticals (Delaware).

About Actinium Pharmaceuticals (Delaware)

ATNM stock →

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

ATNM vs CUE FAQ

Which is bigger, Actinium Pharmaceuticals (Delaware) or Cue Biopharma?

Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).

Which stock has performed better over the past year, ATNM or CUE?

ATNM returned -21.05% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.

Are Actinium Pharmaceuticals (Delaware) and Cue Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons